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Durham, NC, USA; Eldoret, Kenya; Providence, RI, USA; and New York, NY, USAEach day, over 3 billion people residing mostly
in low- and middle-income countries (LMIC)
prepare meals on inefﬁcient cook stoves or heat
their homes using biomass fuel exposing billions
of people to household air pollution (HAP) [1].
In recent years, international attention has focused
on the health effects of exposure to HAP in such
countries [2e5]. The World Health Organization
estimates that 2 million people die each year as
a result of exposure to HAP with the bulk of
this mortality estimate based on deaths due to
childhood acute respiratory infections, chronic
obstructive pulmonary disease (COPD), and
lung cancers [6].
Emerging evidence and research based on ambient
air pollution also implicatesHAP in the development
of cardiovascular diseases such as myocardial
ischemia, high blood pressure, and congestive heart
failure, as well as with elevated right heart pressures
[7e9]. Cardiopulmonary diseases such as pulmonary
hypertension (PH) and right heart failure (RHF)
are common in LMIC and are often associated
with human immunodeﬁciency virus (HIV), schisto-
somiasis, parenchymal destruction from tuberculosis,
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(gerald.bloomﬁeld@duke.edu).[5,10]. Little is known, however, about the interplay
between HAP, right heart function, and these
common comorbidities in LMIC. Understanding
these relationships is important so that themagnitude
of the effect ofHAPonPHand right heart function is
understood and appropriate measures are taken to
reduce the associated morbidity.
This review begins by highlighting what is
known about the common causes of PH in LMIC
using the international PH classiﬁcation framework
and highlighting conditions speciﬁc to LMIC. We
then discuss HAP and its relationship to PH and
RHF. Based on the disproportionate distribution
of PH and RHF worldwide, we propose that the
presence of certain comorbidities speciﬁc to
LMIC may predispose individuals exposed to
HAP to developing PH and RHF (Fig. 1). Where
data are available, we review the literature regarding
the effects of pre-existing comorbidities on the
impact of exposure to HAP on PH and subsequent
RHF in LMIC. Where data are lacking, we present
a conceptual framework of the unique comorbid
factors in LMIC that may predispose people to
developing PH and RHF when exposed to HAP.
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250patients exposed to HAP who develop isolated
RHF may have no other predisposing factors and
this group of patients deserves further study. By
offering this conceptual framework on conditions
speciﬁc to LMIC, HAP, PH, and RHF, our ulti-
mate aim is to highlight the multifactorial nature
of these complex relationships and suggest ripe
avenues for further investigation.
PH AND RH F I N LM I C
Most of what is known about the epidemiology of
PH and RHF is based on registries from American
and European populations; the actual prevalence in
the LMIC remains to be determined [11]. Diag-
nostic challenges are a major limitation and whereas
noninvasive methods of PH assessment (e.g., elec-
trocardiography, echocardiography) may be more
accessible and widespread in LMIC, they are not
as accurate as invasive measurement of pulmonary
pressures by cardiac catheterization [12]. Available
data, however, suggest that 20 to 25 million people
in LMIC have some form of pulmonary vascular
disease, representing >97% of the global burden
[13]. RHF appears to be among the leading typesFig. 1. Factors contributing to the burden of PH and RHF in LMIC.
(LMIC) (green boxes) each can predispose individuals to developing pu
(grey arrows). Household air pollution (HAP) (blue triangle) may also ca
LMIC may be due to a background predisposition related to the presen
arrow). HIV, human immunodeﬁciency virus; TB, tuberculosis.of heart failure in sub-Saharan Africa (SSA) if
data from the Heart of Soweto study can be gener-
alized [14]. In this study from South Africa, RHF
was among the top 3 types (27%) of 844 de novo
cases of heart failure seen in an urban setting, along
with hypertensive heart disease (33%) and idio-
pathic dilated cardiomyopathy (28%) [14].
The current classiﬁcation system for PH (the
Dana Point classiﬁcation) was adopted in 2008 by
the World Symposium on PH [15]. The causes of
PH are divided into 5major groups and 28 subgroups
based on shared pathophysiologic mechanisms, clin-
ical presentations, and therapeutic approaches. As
such, the causes of PH are many, but only a few are
thought to be responsible for the disproportionately
high burden of PH in LMIC. Left-sided heart
diseases (group 2) are commonly associated with
developing PH and by the time PH is present, left-
sided heart diseases are usually severe and not clini-
cally or echocardiographically silent. In many cases,
however, the clinician caring for a patient with seem-
ingly “idiopathic” PH needs to have a high clinical
suspicion for causes of PH in other groups where
local epidemiology is often the basis of a presumptive
diagnosis. We focus on the relationship betweenCommon comorbidities found in low- and middle-income countries
lmonary hypertension (PH) and subsequent right heart failure (RHF)
use PH and RHF directly (blue arrow). The high burden of PH/RHF in
ce of these comorbidities and subsequent exposure to HAP (orange
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251HAP and causes of PH from group 1 (pulmonary
arterial hypertension associated with speciﬁc condi-
tions), group 3 (pulmonary hypertension owing to
lung diseases and/or hypoxia), and group 4 (chronic
thromboembolic PH) because, despite the fact that
the majority of cases worldwide are thought to fall
into these categories, these conditions are perhaps
less often considered and may represent more of a
diagnostic challenge [13].
COMMON CAUS E S O F PH I N LM I C
Human immunodeﬁciency virus. Considering the
global number of HIV-infected individuals, 67%
(22.1 million) reside in SSA with the majority of
deaths globally due to HIV occurring in this region
[16]. HIV-associated PH is included under group
1.4.2 of the PH classiﬁcation system [15]. This
condition is a rare noninfectious pulmonary com-
plication associated with HIV and is estimated to
occur in 0.6% to 5% of patients with HIV in
LMIC [17]. The prevalence of PH is 6 to 12
greater in HIV seropositive (HIVþ) persons com-
pared with HIV seronegative (HIVe) persons [18].
Echocardiography-based studies of HIVþ persons
suggest that as many as 35% have pre-clinical PH,
but only 27% of persons with PH suspected by
echocardiography will meet diagnostic criteria based
on right heart catheterization [19]. The mean age of
presentation with HIV-associated PH is 38 to 41
years, but may range from infancy to old age,
affecting men more than women in a ratio of 1.2:1
[20]. Studies have not found any signiﬁcant corre-
lation between HIV-associated PH and viral load or
CD4 T-cell count, although HIV-associated PH
tends to be severe in the presence of acquired
immunodeﬁciency syndrome (AIDS) [20].
HIVþ persons with PH exhibit increased
mortality compared with counterparts who are
HIVþ without PH with a 3-year survival rate of
70% [20,21]. Fifty percent of deaths reported in
patients with HIV-associated PH are related to
noninfectious causes such as right ventricular
failure or sudden cardiac death and not to HIV/
AIDS [20]. The impact of combined antiretroviral
therapy on PH is still debated. Study results range
from combined antiretroviral therapy having no
effect to accelerating the development
of PH [22,23].
The mechanism of PH in HIVþ patients is
thought to be related to chronic inﬂammation and
immune system activation [17]. The HIV virus
has not been shown to infect lung tissue directly.The histopathologic characteristics of HIVe-
associated PH are similar to those of idiopathic
PH, manifesting as obliterated pulmonary vascula-
ture with medial hypertrophy, endothelial cell
proliferation, and increased expression of ﬁbroblast
growth factors and perivascular inﬂammatory cells
[24]. The resulting clinical manifestation is charac-
terized by progressive shortness of breath and
fatigue, which is similar among patients in LMIC
as well as in developed countries [24].
Schistosomiasis. Schistosomiasis is an important
neglected ﬂatworm tropical disease that is
estimated to afﬂict more than 200 million people
globally. Pulmonary hypertension due to schistoso-
miasis infection falls under group 1.4.5 causes of
PH and is found in 1% to 5% of individuals chron-
ically infected [15,25]. Schistosomiasis is endemic
in 74 countries, with a reported 85% of the
infected individuals living in SSA [26]. After being
ingested, the adult worms stay in the superior
mesenteric vein, producing about 300 ova per day.
Ova, which are not excreted, are transported to the
liver via the portal vein, where they lodge and die,
evoking a granulomatous reaction around the
hepatic veins that develops into ﬁbrosis [13]. This
results in portal hypertension that diverts blood
from the mesenteric veins to pulmonary circulation.
When this conduit matures, the ova are able to
reach pulmonary circulation, where they cause
vascular changes that lead to PH. Pulmonary
disease is seldom seen in the absence of hep-
atosplenic disease [27]. After treatment, likelihood
of recovery from acute pulmonary schistosomiasis
(Katayama fever) without any residual pulmonary
disease is good. In contrast, chronic pulmonary
schistosomiasis, a major long-term consequence
of schistosomiasis infestation in endemic areas,
leads to vascular remodeling and pulmonary
hypertension accounting for up to 30% of cases of
PH in South America [28]. There is also important
overlap between HIV and schistosomiasis in terms
of the high risk and rate of coinfection [29] and the
effect of schistosomiasis on the host response
to HIV [30].
Hemoglobinopathies. Hemoglobinopathies are an
important cause of PH and are included in category
1.4.6 of the updated PH classiﬁcation system [15].
Several hemoglobinopathies disproportionately
burden individuals from LMIC and, therefore, are
likely candidate comorbidities that may exacerbate
the impact of HAP on PH and RHF. Sickle cell
disease (SCD) is an autosomal recessive Mendelian
disease that disproportionately burdens populations
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252of SSA [31]. Beta thalassemia, a group of inherited
blood disorders characterized by reduced or absent
synthesis of the beta chains of hemoglobin, is
analogously more common among southeast
Asian populations [32].
The mechanisms of PH and RHF in individuals
with hemoglobinopathies have been described [33].
In these conditions, hemolysis releases cell-free
hemoglobin that then oxidizes nitric oxide to
nitrate, causing vasoconstriction and subsequent
pulmonary vasculopathy [34]. Other mechanisms
for PH include functional asplenia, thromboembo-
lism, pulmonary ﬁbrosis, and hypoxemia [35].
Notably, because well-treated beta thalassemia
major patients (regular transfusion and chelation
therapy) do not generally develop PH, it appears
that hemolysis and its effects on tissue hypoxia
play a key role in the development of PH in
these patients [36].
Up to one-third of individuals with SCD have
PH deﬁned by echocardiography or by right heart
catheterization [37]. SCD can cause RHF in the
absence of PH, but PH exacerbates or triggers
RHF in the majority of cases [34]. During an acute
chest syndrome, pulmonary pressures can acutely
rise and trigger RHF in about 13% of patients,
particularly among patients with pre-existing base-
line PH or right ventricular dysfunction [38]. The
prevalence of PH and RHF among patients with
beta thalassemia depends on the severity of disease
(thalassemia major versus intermedia), on adequacy
of treatment and modality of PH assessment [39].
Untreated thalassemia major patients nearly univer-
sally develop PH [40]. Notably, thalassemia inter-
media patients are more likely to develop PH than
treated thalassemia major patients are, likely due
to the protective effects of transfusion and chelation
therapy in thalassemia major individuals [36]. In 1
series of thalassemia intermedia patients, nearly
60% were found to have PH [41]. Given the high
prevalence of hemoglobinopathies in SSA and
Southeast Asia and the strong association between
hemoglobinopathies and PH, a large number of
people in LMIC appear to be at risk for developing
PH.
Chronic obstructive pulmonary disease. COPD is
a leading cause of morbidity and mortality worldwide
and a recognized cause of PH (group 3.1 causes)
[15]. Although precise data are lacking due to vari-
able deﬁnitions of the disease and inconsistent data
reporting, the World Health Organization estimates
the world COPD mortality, incidence, and preva-
lence rates per 100,000 to be 44.2, 92.1, and 1,013,respectively. The highest rates were seen in the
Western Paciﬁc (mostly China) (79.8, 176.6, and
1,675) and the lowest rates in Africa (18.1, 29.8, and
179). For Africa, these lower COPD rates may
reﬂect a lack of cigarette smoking, younger age of the
population, or the result of a paucity of reported data
[42]. However, with the rapid rise in cigarette
smoking rates reported in LMIC (2% annually),
especially in Africa (3.2% annually), COPD rates are
predicted to greatly increase in these countries over
the next decade [43].
COPD can be complicated by the development
of PH and RHF, worsening both patient quality
of life and survival. Hypoxemia-induced vasocon-
striction and destruction of the pulmonary vascular
bed are responsible mechanisms. Short-term hypox-
emia leads to pre-capillary arteriole vasoconstriction
in an attempt to lessen ventilation/perfusion mis-
match with complete reversibility on correction of
the hypoxemia. In contrast, chronic hypoxemia
associated with advanced COPD causes the release
or suppression of mediators responsible for vascular
tone and vascular cell proliferation. The resulting
alteration in vascular function leads to vessel remod-
eling and destruction, as well as the onset of persis-
tent PH that is refractory to correction with
supplemental oxygen. The prevalence of PH among
patients with COPD varies widely among reports
and this is likely due to the populations studied
and the methodology used to deﬁne PH. In general,
the magnitude of PH is modest with severe PH
being uncommon [44].
Interstitial lung disease. There are over 200
diseases that result in interstitial lung disease
(ILD). In LMIC, inhalation of inorganic dusts
(e.g., silica, coal, asbestos) [45], sarcoidosis [46],
and HIV-associated lymphocytic interstitial pneu-
monia in children [47] are common causes of ILD.
Unfortunately, no large epidemiologic studies are
available to estimate the prevalence or incidence of
ILD in LMIC. However, several small series
suggest that the disease entity may be a signiﬁcant
contributor to lung morbidity and mortality [48].
As ILD slowly progresses over many years, respi-
ratory failure and PH with RHF often develop.
Parenchymal and vascular remodeling are the
primary mechanisms responsible for the relatively
high prevalence of PH in ILD [49].
Effective treatment for ILD remains elusive,
even in developed nations. For those living in
LMIC, limiting exposure and instituting appro-
priate therapy of the causative conditions may be
the most successful interventions to lessen the
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253severity of ILD and subsequent PH and RHF. The
mortality rate from ILD remains high as diagnostic,
referral, and therapeutic options are limited in many
LMIC.
Healed tuberculosis infection. Tuberculosis (TB)
remains a leading cause of disease, mortality, and
morbidity in the world with World Health Organi-
zation reporting an estimated 8.8 million cases
occurring in 2010 and 1.4 million resultant deaths
[50]. Though not a unique subgroup within the
PH classiﬁcation system, TB-associated PH is most
similar to group 3 PH disorders [15]. Although
curable in the majority of cases with prolonged
antibiotic courses (minimum of 6 months), TB
may result in marked lung destruction (ﬁbrosis,
bronchiectasis, bronchovascular distortion, and/or
emphysema) with consequent pulmonary physio-
logical effects. These effects range to as high as over
50% of post-TB patients demonstrating physio-
logical impairment [51]. One study of South
African miners demonstrated progressive loss of
function associated with each recurrent case of TB,
progressing from 18% following 1 episode to 35%
after 3 episodes of disease [52]. The amount of
destruction may also be related to the length of time
preceding diagnosis and institution of effective
therapy [53]. Thus, resultant long-term pulmonary
disability related to tuberculosis is likely to be more
common in resource-limited regions where diag-
nosis and effective therapy are often delayed and
where both pulmonary physiological assessments as
well as effective pulmonary management is also
limited.
Multiple studies from regions as diverse as
Indonesia [54], the United States [55], South Africa
[51], and Latin America [56] have all demonstrated
lung function impairment at the end of TB therapy.
Impaired pulmonary physiology with resultant gas
exchange abnormalities have clearly been shown
to be a risk factor for secondary PH. One study in
Ethiopia has examined the occurrence of PH in
“healed” tuberculosis patients [57]. In this small series
(N ¼ 14), all patients had not only physiologic
pulmonary impairments but also radiologic pulmonary
abnormalities in association with their pulmonary
hypertension (estimated pulmonary artery systolic
pressures 40 to >80 mm Hg). The relationship of
tuberculosis to pulmonary hypertension appears to
be related not through a direct effect of the infectious
agent but rather through the degree of parenchymal
damage left in the wake of curative therapy.
High altitude. Living at high altitude is a well-
known risk factor for PH and is a designatedsubset of PH in group 3.5 of the updated classi-
ﬁcation system [15]. High altitude causes chronic
hypoxemia, which then causes hypoxia-induced
pulmonary vasoconstriction and vascular remodel-
ing of pulmonary arterioles. This ultimately leads
to increased pulmonary vascular resistance and PH.
Many regions of LMIC are located at high alti-
tudes, particularly in Asia, Africa, and Latin
America, and a signiﬁcant number of people live in
high-altitude areas. In fact, an estimated more than
140 million people live 2,500 m above sea level,
and the majority of these individuals live
in LMIC [58].
Epidemiological studies of high-altitude PH have
revealed a prevalence of between 5% and 25%, with
notable geographic diversity [59]. In high-altitude
regions of Kyrgyzstan, men were more likely to
have electrocardiographic evidence of RHF than
women were (23% vs. 6%) [60]. In the Andean
region, prevalence of PH has been reported as
between 5% and 18% [59]. In the Qinghai Province
of China, high-altitude PH was more common
among children than among adults [61]. Notably,
Tibetan populations generally have less PH and
exercise-induced PH than other high-altitude popu-
lations for unknown reasons [62]. RHF caused by
exposure to PH at high altitude also appears to be
region-speciﬁc. Whereas high-altitude RHF is
common among individuals with high-altitude PH
in China and Tibet, severe RHF is relatively less
common in the Andean region among those
with PH [59].
Chronic thromboembolic pulmonary hyper-
tension. Chronic thromboembolic pulmonary
hypertension (CTEPH) is group 4 of the PH classi-
ﬁcation system [15]. CTEPH is traditionally
thought to occur in less than 1% of survivors of acute
pulmonary embolism [63]; however, that estimate
could be much higher owing to substantial under-
diagnosis. For example, a prospective, long-term
study to assess the incidence of symptomatic
CTEPH among consecutive index cases of acute
pulmonary embolism in Italy described an incidence
close to 4% after 2 years of follow-up [64]. In China,
as the magnitude of pulmonary embolism has
increased dramatically (10-fold increase in number of
cases between 1997 and 2008), there has been a
commensurate heightened national awareness of the
importance of CTEPH as a cause of PH [11]. It is
the remodeling of the pulmonary resistance vessels
rather than recurrence of pulmonary embolism that is
thought to lead to the development of pulmonary
arterial hypertension and RHF [65]. Even then, the
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254exact pathophysiologic mechanisms leading to
vascular remodeling remain poorly understood.
Where resources are limited, CTEPH repre-
sents a diagnostic challenge and underdiagnosis is
expected to be more common. In LMIC, history
and physical examination are especially important
in diagnosing CTEPH because the symptoms
and signs may be quite subtle. Progressive exer-
tional dyspnea is the most consistent presenting
complaint. Chest pain, near-syncope or syncope,
and lower extremity edema are late symptoms.
Many patients provide a history consistent with
an acute pulmonary embolic event, although docu-
mentation of prior thromboembolism may be
absent [66]. Physical examination remains unre-
markable until late in the disease progression. It
is not unusual in LMIC for patients to present
with overt signs of right-sided heart failure. In
many centers, basic laboratory tests (e.g., D-dimer)
and chest X-ray may be available, whereas more
advanced investigations (e.g., brain natriuretic
peptide, transthoracic echocardiography, computed
tomography scanning, spirometry) are usually
found in referral centers, highlighting the signiﬁ-
cant diagnostic challenges. In western Kenya, for
example, the most common diagnostic approach
begins with a clinical and echocardiographic evalu-
ation. Subsequent investigations supported by
Doppler ultrasonography of extremity vasculature,
chest radiography (X-ray and/or computed tomog-
raphy scan) and spirometry may lead to a working
diagnosis of CTEPH. It should be noted that even
these seemingly basic tests can only be performed
at the national referral hospital in the region and
are not universally accessible due to cost
implications.
DO COMMON CAUS E S O F PH
POT EN T I A T E TH E ADV E R S E E F F E C T S
O F HA P ?
We now turn our attention to the interplay between
the aforementioned conditions, HAP, PH, and
RHF. In most instances, the pathway suggested in
Figure 1 has not been demonstrated empirically
but appears plausible based on similarities in
geographic distribution, pathophysiology, and
research from other forms of air pollution. In parts
of the world where HAP is prevalent, the burden
of HIV, schistosomiasis, hemoglobinopathies, and
tuberculosis are also common. In Malawi, for
example, the HIV prevalence rate is among the top
10 in the world and >95% of households burnbiomass fuels indoors [67]. There is also substantial
overlap between high-altitude regions of the world
and regions where there is signiﬁcant exposure to
HAP, due to the use of biomass fuels for heating
as well as cooking. In the Himalaya mountains of
northern India, measures of HAP were greater in
the winter than in the summer, due to increased
use of biomass fuels for heating in the winter months
[68], contributing to altitude-speciﬁc respiratory
morbidity [69]. Similarly, in Peru, HAP measures
were greater during the morning meal preparation
time when both dung and wood were used as
cooking fuels [70].
Pathophysiologic similarities also lend credibility
to the potentiating effects of HAP on other forms of
PH. HIV infection can impair lung function
directly [71], as well as increase the host’s suscepti-
bility to lung infections [72], both of which may
predispose to PH. HIV and HAP exposure are
also both associated with an increased risk of pneu-
monia and have similar effects on pulmonary
inﬂammation [73]. HAP has been associated with
bronchitis and asthma in the highland regions of
Bolivia [74] and Guatemala [75], suggesting that
high altitude may potentiate or exacerbate the
impact of HAP on PH and RHF.
Though the exposures and dose are different
between HAP and tobacco smoking [7], parallel
relationships also support the potentiating effect of
other forms of PH on HAP. HIVþ tobacco
smokers are at higher risk than nonsmokers are to
develop pulmonary emphysema [76] and tobacco
smoking is posited to exacerbate the effects of
HIV on lung function [77]. With regard to hemo-
globinopathies, tobacco smoke has been associated
with increased risk of sickle cell crises [78]. Like-
wise, poor outdoor air quality has been associated
with increased hospitalizations for acute sickle cell
pain [52]. Smoking tobacco is a moderate risk factor
for venous thromboembolism, whereas higher levels
of ambient air pollution (particulate matter <10 mm
in aerodynamic diameter or PM10) are associated
with a greater risk of deep venous thrombosis
[79,80]. CTEPH has not speciﬁcally been studied
in this regard and less is known with regard to schis-
tosomiasis and tuberculosis and any potential
synergy with HAP.
The literature is slightly more robust for COPD
and ILD. HAP appears to be an important risk
factor for the development of COPD in LMIC.
Numerous population-based, cross-sectional, and
case-control studies have found that indoor cooking
with biomass fuels is a major risk factor for the
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255development of COPD in resource-poor countries
[5,81]. Women living in rural areas seem to be
especially vulnerable [82]. For example, Smith
et al. [4] report that women exposed to HAP
from wood burning were 3.2 (95% conﬁdence
interval: 2.3 to 4.8) as likely to develop COPD as
those who cook and heat with electricity, gas, and
other cleaner fuels. In a study of 5,539 subjects
from Colombia, cooking for 10 years or more
with a wood stove was found to be an independent
risk factor for the development of COPD even after
adjusting for factors such as age, sex, active and
passive smoking, education level, history of tubercu-
losis, and exposure to charcoal or dust at work [83].
Noteworthy in this study, men were also at risk for
COPD but to a lesser degree than women were
(odds ratio: men: 1.53 vs. women: 1.84), suggesting
a high level of pollutants in the home cooking
environment.
Whether a direct link exists between HAP expo-
sure and right heart function independent of
chronic obstructive lung disease is unclear but it is
noteworthy that the burden of PH seen in patients
with COPD is modest compared with the degree of
PH seen in LMIC. The attributable risk of RHF
due to HAP separate from the impact of COPD
will be difﬁcult to assess as HAP exposure contrib-
utes simultaneously to RHF via direct and pulmo-
nary pathways (Fig. 1). Further research is needed
to determine if reducing HAP can lessen the devel-
opment of COPD and associated PH and RHF.
Reducing HAP, however, can reduce the incidence
of COPD in LMIC. Since the 1980s, the Chinese
National Improved Stoves Program has installed
over 180 million improved stoves in rural house-
holds. In 1 retrospective Chinese cohort study, stove
improvement was associated with a reduction in
COPD incidence [84]. Further, in a community
intervention trial in Mexico, forced expiratory
volume in 1 s declined by 31 ml/year in women
using a fuel-efﬁcient, low-emission stove compared
with 62 ml/year in women cooking over open wood
ﬁres [85]. Non-HAP-associated COPD (i.e., due
to tobacco smoking) is a growing potential source
of underlying lung disease in LMIC [43] and rela-
tively little is known of its interaction with HAP to
contribute to PH/RHF.
HAP has been associated with ILD in numerous
case series from several different countries and this
association forms the bulk of the literature on
HAP and cardiopulmonary pathology. Restrepo
et al. [86] found 22 cases of pneumoconiosis related
to the inhalation of wood smoke ﬂy ash withsilicates in the mountain area of Colombia; lung
biopsies revealed ﬁbrosis and anthracosis (deposi-
tion of carbon, silica, and quartz particles in the
macrophages, mucosa, and submucosa). Similarly,
Sandoval et al. [87] reported 22 women from rural
Mexico who had micronodular or reticular opacities
on chest roentgen scans associated with wood
smoke. The anthracotic deposits were thought to
result not so much from the wood burning itself
but from the combination of the type of stoves
used, the local cooking practices, and the ﬂoor
materials in the cooking area. This complex combi-
nation of risk factors is also illustrated by the docu-
mentation of “hut lung” found in South African
women. With this disease, a combination of respi-
rable quartz during maize grinding, nonquartz
dust, and smoke from dung were all responsible
for the interstitial disease, with the latter 2 being
the more important risk factors [88]. Finally, Has-
san et al. [89] found that chronic exposure to pine-
wood smoke in India resulted in “Gujjar lung,” an
interstitial disease that was characterized by reticu-
lonodular opacities on chest roentgen scans and
anthracotic nodules, carbon laden macrophages,
and ﬁbrosis on lung biopsy.
I S T H E R E A D I R E C T L I N K B E TWE EN HAP
AND RH F ?
As Pandey [90] describes in this issue, over 50 years
of research, mostly in the form of case series, has
shown a relationship between exposure to HAP
and right-sided cardiac pathology in LMIC
[87,91e93]. HAP has also been implicated as a
cause of isolated RHF in epidemiological studies.
In the Heart of Soweto study, most of the cases of
RHF were young women with isolated RHF and
idiopathic was the most common etiology of PH
(34% and 66% of cases for women and men, respec-
tively) after an exhaustive search for other causes
[10]. Based on common exposures in this region,
HAP from burning solid fuels has been postulated
to be an important contributor to the otherwise
idiopathic RHF in South Africa but a deﬁnitive
link has not been speciﬁcally examined.
There is increasing evidence that PH and RHF
occur at an increased rate in settings where HAP is
an ongoing problem. Although direct causality has
not been proven, it is highly likely that a link among
HAP, PH, and subsequent RHF exists. This explor-
atory review suggests that HAP may play an indirect
role in the development of RHF and pulmonary
hypertension. For instance, HAP is a known risk
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256factor for the development of COPD that then
predisposes patients to the occurrence of PH via
hypoxemia-induced vasoconstriction and increased
airway inﬂammation. Alternatively, HAP may
exacerbate underlying lung disease, thus causing
increased inﬂammation and vascular remodeling
that subsequently causes RHF [5]. However, several
case reports indicate the presence of a unique cohort
of patients in whom PH exists in spite of a lack of
obvious secondary causes [91,93]. In western Kenya,
isolated PH has been reported in middle age and
older women without any underlying lung disease
and no other known risk factors of PH [91]. It is
these cases of PH that are especially intriguing. It
is plausible that HAP plays an integral role in the
development of isolated PH via various mechanisms,
including the promotion of vascular remodeling.
Whether this condition is reversible by the removal
of continued exposure to biomass by-products
remains to be seen.
Exposure to household air pollutants such as
wood smoke particulate matter results in increased
oxidative stress with production of reactive oxygen
species, increased secretion of proinﬂammatory cyto-
kines including tumor necrosis factor alpha, and
alterations in endothelin receptor expression [94].
Endothelin 1, for example, is a vasoactive peptide
that acts as a potent vasoconstrictor in the lungs. In
animal models, inhalation of urban particles (Ottawa
dust) and ozone increases endothelin-1 expression
[95]. In a study of children living in Mexico City,
elevations in serum endothelin-1 levels were corre-
lated with exposure to outdoor air pollutants (7-day
cumulative levels of PM2.5) and the presence of
elevated pulmonary pressures [96]. These ﬁndings
suggest that inhalation of air pollutants could result
in an increased risk of vascular remodeling and thus
the development of PH.
There is a paucity of research focused on isolated
RHF in LMIC despite mounting evidence support-
ing the signiﬁcant morbidity associated with this
disease in otherwise healthy individuals. There is a
desperate need for well-characterized studies. There
are signiﬁcant barriers to research in this area, the
most important of which is a lack of research fund-
ing that impedes progress in discovering novel
mechanisms of disease and subsequently the dis-
covery of appropriate therapies for patients afﬂicted
with PH and RHF. The lack of resources stems
from poor recognition of the magnitude of the
problem and indeed studies are required to deter-
mine the exact prevalence of seemingly isolated
RHF in populations where the use of biomassfuel is common. Additional barriers include poor
access to medical care and a lack of the technolog-
ical tools required to completely evaluate patients
presenting with RHF. The importance and
complexity of determining the contribution of
various factors to the ultimate development of
RHF cannot be overstated. Increased awareness of
this disease would lead to a determination of appro-
priate therapy for these patients and would
undoubtedly have a signiﬁcant impact on the lives
of a large population.
CONC LU S I ONS
The burden of PH and RHF in settings where
HAP is prevalent is greater than the burden of
PH and RHF seen in chronic lung diseases such
as COPD [44]. There has been little attention
paid to the association between exposure to HAP
and cardiovascular diseases independent of apparent
lung disease [4]. This may be related to a perceived
lack of evidence. The only HAPecardiovascular
disease relationship supported by randomized trial
evidence and observational studies is that of blood
pressure [97e100]. Ambient air pollution has
been linked to myocardial ischemia, heart failure
exacerbations, and overall cardiovascular mortality
[8]. Relatively little attention has been paid to
assessing PH or right ventricular dysfunction in
patients with HAP exposure in the setting of
comorbidities affecting cardiopulmonary health,
especially in LMIC. Nevertheless, clinical experi-
ence and small studies lend credence to the utility
of systematically exploring these relationships.
We suggest that more consideration should be
given to the impact of pre-existing, and perhaps
subclinical, comorbidities on the likelihood of HAP
causing PH and RHF. The challenges inherent in
establishing this proposed linkage rest in research
methodology but are also compounded by the fact
that these types of conditions are most common in
settings where diagnostic and therapeutic resources
are limited. Nevertheless, given the large number of
individuals who have or are at risk for developing
PH in LMIC, a concerted effort to address these
relationships is certainly warranted. This is especially
pertinent and timely given the growing international
attention in HAP and its health effects, and large-
scale efforts to implement solutions to reduce or
eliminate it. By reviewing and positing these rela-
tionships, our goal is to spark a dialogue and further
investigation into conditions that disproportionately
affect the most disadvantaged.
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